93 related articles for article (PubMed ID: 2232966)
1. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.
Mallmann P; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Jun; 12(5):333-40. PubMed ID: 2232966
[TBL] [Abstract][Full Text] [Related]
2. [The effect of adjuvant combined chemo/immunotherapy on immunological parameters and clinical course in patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):697-706. PubMed ID: 1927119
[TBL] [Abstract][Full Text] [Related]
3. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
4. [The effect of immunotherapy with thymopentin on the parameters of cellular immunity and the clinical course of gynecologic tumor patients].
Mallmann P; Krebs D
Onkologie; 1989 Jun; 12 Suppl 3():15-21. PubMed ID: 2532730
[TBL] [Abstract][Full Text] [Related]
5. [Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):689-96. PubMed ID: 1927118
[TBL] [Abstract][Full Text] [Related]
6. Determination of TNF alpha, interferon alpha, interleukin 2 and reactivity in the leucocyte migration inhibition test in breast cancer patients.
Mallmann P; Diedrich K; Mallmann R; Koenig UD; Krebs D
Anticancer Res; 1991; 11(4):1509-15. PubMed ID: 1746907
[TBL] [Abstract][Full Text] [Related]
7. Successful restoration of cell-mediated immune response after cardiopulmonary bypass by immunomodulation.
Markewitz A; Faist E; Lang S; Endres S; Fuchs D; Reichart B
J Thorac Cardiovasc Surg; 1993 Jan; 105(1):15-24. PubMed ID: 8419695
[TBL] [Abstract][Full Text] [Related]
8. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
9. Changes in lymphocyte subsets and mitogen responsiveness following open-heart surgery and possible therapeutic approaches.
Markewitz A; Faist E; Niesel T; Lang S; Weinhold C; Reichart B
Thorac Cardiovasc Surg; 1992 Feb; 40(1):14-8. PubMed ID: 1385913
[TBL] [Abstract][Full Text] [Related]
10. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.
Nicolini A; Carpi A; Rossi G
Cancer Lett; 2007 Jun; 251(2):330-8. PubMed ID: 17215077
[TBL] [Abstract][Full Text] [Related]
11. Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy.
Mendonça MA; Cunha FQ; Murta EF; Tavares-Murta BM
Cancer Chemother Pharmacol; 2006 May; 57(5):663-70. PubMed ID: 16133528
[TBL] [Abstract][Full Text] [Related]
12. Effect of a combination of extract from several plants on cell-mediated and humoral immunity of patients with advanced ovarian cancer.
Kormosh N; Laktionov K; Antoshechkina M
Phytother Res; 2006 May; 20(5):424-5. PubMed ID: 16619374
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
15. [Effect of systemic chemotherapy on clinical status and biological and immunologic markers in patients with breast cancer].
Orlova RV; Chernetsova LF; Matveeva ON
Vopr Onkol; 2007; 53(4):414-8. PubMed ID: 17969403
[TBL] [Abstract][Full Text] [Related]
16. Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer.
Fredrikson M; Fürst CJ; Lekander M; Rotstein S; Blomgren H
Brain Behav Immun; 1993 Mar; 7(1):79-90. PubMed ID: 8471800
[TBL] [Abstract][Full Text] [Related]
17. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method.
Svane IM; Nikolajsen K; Hansen SW; Kamby C; Nielsen DL; Johnsen HE
Bone Marrow Transplant; 2002 Apr; 29(8):659-66. PubMed ID: 12180110
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer.
Recchia F; Saggio G; Cesta A; Candeloro G; Nuzzo A; Lombardo M; Carta G; Rea S
Int J Oncol; 2005 Oct; 27(4):1039-46. PubMed ID: 16142321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
